Idiosyncratic drug-induced agranulocytosis

被引:10
作者
Andrès, E
Maloisel, F
机构
[1] Hop Univ Strasbourg, Serv Med Interne, Clin Med B, F-67091 Strasbourg, France
[2] Hop Univ Strasbourg, Dept Oncohematol, F-67091 Strasbourg, France
来源
REVUE DE MEDECINE INTERNE | 2006年 / 27卷 / 03期
关键词
agranulocytosis; neutropenia; drug; latrogenic effect; fever; hematopoietic growth factor;
D O I
10.1016/j.revmed.2005.06.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. - Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs. Current data. - Idiosyncratic drug-induced agranulocytosis is characterized by a neutrophil count < 0.5 x 10(9)/1, in serious forms < 0,1 x 10(9)/1 that Currently Occurs especially in association with antibiotics, antithyroid drugs ant ticlopidine (> 60% of the incriminated drugs). The overall incidence of idiosyncratic agranulocytosis ranges from 2.4 to 15.4 cases per million patients exposed to drugs per year. Although patients experiencing idiosyncratic agranulocytosis may be asymptomatic (50%), the severity of the neutropenia usually leads to severe sepsis: fever of unknown origin, septicemia, septic shock or localized documented infections Such as sore throat, various Cutaneous infections or pneumonia. Nevertheless, the mortality rate of idiosyncratic agranulocytosis is now around 5% with appropriate management. Perspectives. - In the future, management of drug-induced agranulocytosis may include pre-established procedures using in critically situations, broad-spectrum antibiotic therapy and hematopoietic growth factors (G-CSF). (c) 2005 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 46 条
[1]  
Alter BF, 1993, APLASTIC ANEMIA ACQU, P227
[2]   Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients [J].
Andrès, E ;
Noel, E ;
Kurtz, JE ;
Loukili, NH ;
Kaltenbach, G ;
Maloisel, F .
DRUGS & AGING, 2004, 21 (07) :427-435
[3]   Long-term outcome of patients treated with hematopoietic growth factors for idiosyncratic drug-induced agranulocytosis [J].
Andrès, E ;
Noel, E ;
Maloisel, F .
AMERICAN JOURNAL OF MEDICINE, 2004, 116 (05) :354-354
[4]  
Andrès E, 2003, ANN BIOL CLIN-PARIS, V61, P121
[5]   Nonchemotherapy drug-induced agranulocytosis:: interest of haematopoietic growth factors [J].
Andrès, E ;
Noel, E ;
Maloisel, F .
JOURNAL OF INTERNAL MEDICINE, 2002, 251 (06) :533-534
[6]   Nonchemotherapy drug-induced agranulocytosis in elderly patients:: The effects of granulocyte colony-stimulating factor [J].
Andrès, E ;
Kurtz, JE ;
Martin-Hunyadi, C ;
Kaltenbach, G ;
Alt, M ;
Weber, JC ;
Sibilia, J ;
Schlienger, JL ;
Dufour, P ;
Maloisel, F .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (06) :460-464
[7]   Nonchemotherapy drug-induced agranulocytosis:: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature [J].
Andrès, E ;
Kurtz, JE ;
Maloisel, F .
CLINICAL AND LABORATORY HAEMATOLOGY, 2002, 24 (02) :99-106
[8]   Antibiotic-induced agranulocytosis:: A monocentric study of 21 cases [J].
Andrès, E ;
Maloisel, F .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (21) :2619-2619
[9]   Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis [J].
Andrès, E ;
Kurtz, JE ;
Perrin, AE ;
Dufour, P ;
Schlienger, JL ;
Maloisel, F .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (08) :423-428
[10]  
Andres E, 1998, SEM HOP PARIS, V74, P1105